Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
2020 ◽
Vol 19
(5)
◽
pp. 402-412
◽
2019 ◽
Vol 405
◽
pp. 172
◽
2019 ◽
Vol 405
◽
pp. 171
◽
2020 ◽
Vol 19
(5)
◽
pp. 391-401
◽
2020 ◽
Vol 37
◽
pp. 101592
◽
2019 ◽
Vol 405
◽
pp. 11-12
◽